94 related articles for article (PubMed ID: 7513143)
41. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin.
Chen G; Zeller WJ; Todorov DK
Anticancer Res; 1993; 13(5A):1269-75. PubMed ID: 8239496
[TBL] [Abstract][Full Text] [Related]
42. The interaction between a drug and ultrasound in sonochemotherapy against ovarian cancers.
He H; Yu T; Zhang Y
Ultraschall Med; 2012 Jun; 33(3):275-82. PubMed ID: 21165815
[TBL] [Abstract][Full Text] [Related]
43. Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells.
Nessa MU; Beale P; Chan C; Yu JQ; Huq F
Anticancer Res; 2012 Jan; 32(1):53-9. PubMed ID: 22213288
[TBL] [Abstract][Full Text] [Related]
44. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells.
Bonavida B; Tsuchitani T; Zighelboim J; Berek JS
Gynecol Oncol; 1990 Sep; 38(3):333-9. PubMed ID: 2227544
[TBL] [Abstract][Full Text] [Related]
45. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Sharp SY; Rowlands MG; Jarman M; Kelland LR
Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
[TBL] [Abstract][Full Text] [Related]
46. 2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation.
Ellerhorst JA; Frost P; Abbruzzese JL; Newman RA; Chernajovsky Y
Br J Cancer; 1993 Feb; 67(2):209-15. PubMed ID: 7679279
[TBL] [Abstract][Full Text] [Related]
47. Lipid-polymer nanoparticles encapsulating doxorubicin and 2'-deoxy-5-azacytidine enhance the sensitivity of cancer cells to chemical therapeutics.
Su X; Wang Z; Li L; Zheng M; Zheng C; Gong P; Zhao P; Ma Y; Tao Q; Cai L
Mol Pharm; 2013 May; 10(5):1901-9. PubMed ID: 23570548
[TBL] [Abstract][Full Text] [Related]
48. Mechanisms for cisplatin-FUra synergism and cisplatin resistance in human ovarian carcinoma cells both in vitro and in vivo.
Scanlon KJ; Lu Y; Kashani-Sabet M; Ma J; Newman E
Adv Exp Med Biol; 1988; 244():127-35. PubMed ID: 3247881
[TBL] [Abstract][Full Text] [Related]
49. Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor.
Perez RP; Handel LM; Hamilton TC
Gynecol Oncol; 1992 Jul; 46(1):82-7. PubMed ID: 1634144
[TBL] [Abstract][Full Text] [Related]
50. Sequenced Combinations of Cisplatin and Selected Phytochemicals towards Overcoming Drug Resistance in Ovarian Tumour Models.
Althurwi SI; Yu JQ; Beale P; Huq F
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053689
[TBL] [Abstract][Full Text] [Related]
51. Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models.
Nessa MU; Beale P; Chan C; Yu JQ; Huq F
Anticancer Res; 2011 Nov; 31(11):3789-97. PubMed ID: 22110201
[TBL] [Abstract][Full Text] [Related]
52. Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane by digitonin in vitro.
Jekunen AP; Shalinsky DR; Hom DK; Albright KD; Heath D; Howell SB
Biochem Pharmacol; 1993 May; 45(10):2079-85. PubMed ID: 8512589
[TBL] [Abstract][Full Text] [Related]
53. Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines.
Nehme A; Julia AM; Jozan S; Chevreau C; Bugat R; Canal P
Eur J Cancer; 1994; 30A(4):520-5. PubMed ID: 8018412
[TBL] [Abstract][Full Text] [Related]
54. Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin.
Damia G; Tagliabue G; Zucchetti M; Davoli E; Sessa C; Cavalli F; D'Incalci M
Cancer Chemother Pharmacol; 1992; 30(6):459-64. PubMed ID: 1394802
[TBL] [Abstract][Full Text] [Related]
55. Detection and cytotoxicity of cisplatin-induced superoxide anion in monolayer cultures of a human ovarian cancer cell line.
Masuda H; Tanaka T; Tateishi M; Naito M; Tamai H
Cancer Chemother Pharmacol; 2001; 47(2):155-60. PubMed ID: 11269742
[TBL] [Abstract][Full Text] [Related]
56. In vitro enhancement of cis-platinum antitumor activity by caffeine and pentoxifylline in a human ovarian cell line.
Schiano MA; Sevin BU; Perras J; Ramos R; Wolloch EH; Averette HE
Gynecol Oncol; 1991 Oct; 43(1):37-45. PubMed ID: 1959786
[TBL] [Abstract][Full Text] [Related]
57. Antitumor activity of thaliblastine (NSC-68075) in experimental ovarian tumor cell lines sensitive and resistant to cisplatin.
Chen G; Todorov DK; Zeller WJ
Cancer Lett; 1992 Feb; 62(2):173-7. PubMed ID: 1531781
[TBL] [Abstract][Full Text] [Related]
58. Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth.
Scambia G; Ranelletti FO; Benedetti Panici P; Bonanno G; De Vincenzo R; Piantelli M; Mancuso S
Anticancer Drugs; 1990 Oct; 1(1):45-8. PubMed ID: 2131036
[TBL] [Abstract][Full Text] [Related]
59. Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines.
Harstrick A; Schmoll HJ; Sass G; Poliwoda H; Rustum Y
Eur J Cancer; 1993; 29A(7):1000-2. PubMed ID: 8499130
[TBL] [Abstract][Full Text] [Related]
60. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells.
Silvestrini R; Zaffaroni N; Villa R; Orlandi L; Costa A
Int J Cancer; 1992 Nov; 52(5):813-7. PubMed ID: 1428236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
